Form 8-K Aimmune Therapeutics, For: Mar 25
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
Aimmune Therapeutics (AIMT) PT Raised to $58 at RBC Capital
March 26, 2019 6:27 AM EDTRBC Capital analyst Kennen MacKay raised the price target on Aimmune Therapeutics (NASDAQ: AIMT) to $58.00 (from $55.00) while maintaining a Outperform rating.
ARTEMIS reads out positively in Europesetting the stage for a mid-19 MAA filing... More